Search

Your search keyword '"Richardson, Paul"' showing total 1,253 results

Search Constraints

Start Over You searched for: Author "Richardson, Paul" Remove constraint Author: "Richardson, Paul" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
1,253 results on '"Richardson, Paul"'

Search Results

5. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

6. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

9. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

11. Patterns of Gender and Disciplinary Disparities among Postgraduate Students' Motivational Beliefs: A Multivariate Analysis

12. IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab

13. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

14. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

15. Profiles of Teachers' Striving and Wellbeing: Evolution and Relations with Context Factors, Retention, and Professional Engagement

16. Attracting, Retaining and Sustaining Early Childhood Teachers: An Ecological Conceptualisation of Workforce Issues and Future Research Directions

17. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer

18. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

19. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

20. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)

21. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

23. Assessment of Paclitaxel Drug-Coated Balloon Only Angioplasty in STEMI

24. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

27. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

29. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

30. Defibrotide Therapy for SARS-CoV-2 ARDS

32. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

33. A 2D perchlorinated sp2-carbon framework

34. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

35. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

37. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis—study protocol for an interventional randomised controlled trial

38. Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site

39. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

41. Green Chemistry Articles of Interest to the Pharmaceutical Industry.

43. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

45. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial.

47. Teacher Burnout and Turnover Intent

50. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma

Catalog

Books, media, physical & digital resources